Jean-Claude Terrat
Overview
Explore the profile of Jean-Claude Terrat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charra B, Chazot C, Hurot J, Jean G, Terrat J, Vanel T, et al.
Hemodial Int
. 2017 Apr;
4(1):68-74.
PMID: 28455925
Cardiovascular disease is the main cause of the high mortality of dialysis patients and is largely due to poor control of blood pressure. Establishing and maintaining normal extracellular volume (ECV)...
2.
Charra B, Jean G, Hurot J, Chazot C, Vanel T, Terrat J, et al.
Hemodial Int
. 2017 Apr;
4(1):62-67.
PMID: 28455912
Agentle ultrafiltration can be achieved using a long and slow hemodialysis. It is easier to achieve gentle ultrafiltration if the interdialytic weight intake is moderate ( i.e., if the patient...
3.
Charra B, Jean G, Chazot C, Vanel T, Terrat J, Laurent G
Home Hemodial Int
. 2017 Apr;
3(1):16-22.
PMID: 28455858
Long, slow hemodialysis (3 × 8 hours/week) has been used without significant modification in Tassin, France, for 30 years with excellent morbidity and mortality rates. A long dialysis session easily...
4.
Charra B, Jean G, Hurot J, Terrat J, Vanel T, VoVan C, et al.
Hemodial Int
. 2017 Apr;
5(1):42-50.
PMID: 28452432
While nephrologists wait for the ideal, non invasive, inexpensive, precise, and reproducible tool to evaluate extracellular volume (ECV), they need to exert their clinical acumen in the quest of that...
5.
Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B, et al.
Nephrol Ther
. 2010 Jul;
6(6):499-504.
PMID: 20627839
Calciphylaxis (CPX) or calcific uraemic arteriolopathy is a rare life-threatening complication, affecting mainly dialysis patients. The condition is characterized by calcifications and thrombosis of the small cutaneous vessels and small...
6.
Jean G, Vanel T, Terrat J, Hurot J, Lorriaux C, Mayor B, et al.
Nephrol Ther
. 2010 Feb;
6(2):105-10.
PMID: 20185380
Introduction: The treatment of secondary hyperparathyroidism (SHPT) in dialysis patients has changed with the introduction of cinacalcet (CC), which represents a medical alternative to surgical parathyroidectomy (PTX). The aim of...
7.
Jean G, Vanel T, Terrat J, Hurot J, Lorriaux C, Mayor B, et al.
Hemodial Int
. 2009 Sep;
13(4):526-32.
PMID: 19758298
In hemodialysis (HD) patients, mineral metabolism (MM) disorders have been associated with an increased mortality rate. We report the evolution of MM parameters in a stable HD population undergoing long...
8.
Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B, et al.
Nephrol Dial Transplant
. 2009 Apr;
24(9):2792-6.
PMID: 19395730
Background: Fibroblast growth factor (FGF)-23, a novel bone-derived phosphaturic factor involved in mineral metabolism, is increased in chronic kidney disease (CKD); in dialysis patients, it has been linked to increased...
9.
Jean G, Vanel T, Bresson E, Terrat J, Hurot J, Lorriaux C, et al.
Nephrol Ther
. 2009 Apr;
5(4):280-6.
PMID: 19386563
Introduction: Catheter-related adverse events (CAE) remain a major cause of mortality and morbidity. Aim: We aimed to compare the CAE prevalence and adverse events rate at 10 years interval in...
10.
Charra B, Jean G, Chazot C, Hurot J, Terrat J, Vanel T, et al.
Hemodial Int
. 2009 Apr;
8(1):51-60.
PMID: 19379402
The prevalence of hypertension in hemodialysis (HD) patients has increased over the years. In the early days of maintenance HD blood pressure (BP) control was achieved in most patients. As...